

Accepted Manuscript

Title: Use of a collaborative tool to simplify the outsourcing of preclinical safety studies: an insight into the AstraZeneca–Charles-River-Laboratories strategic relationship

Authors: Frederic D.C. Martin, Amanda Benjamin, Ruth MacLean, David M. Hollinshead, Claire Landqvist

PII: S1359-6446(17)30110-1

DOI: <http://dx.doi.org/10.1016/j.drudis.2017.08.007>

Reference: DRUDIS 2070

To appear in:



Please cite this article as: Martin, Frederic D.C., Benjamin, Amanda, MacLean, Ruth, Hollinshead, David M., Landqvist, Claire, Use of a collaborative tool to simplify the outsourcing of preclinical safety studies: an insight into the AstraZeneca–Charles-River-Laboratories strategic relationship. Drug Discovery Today <http://dx.doi.org/10.1016/j.drudis.2017.08.007>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Use of a collaborative tool to simplify the outsourcing of preclinical safety studies: an insight into the AstraZeneca–Charles-River-Laboratories strategic relationship

Frederic D.C. Martin^{1,*}, Amanda Benjamin¹, Ruth MacLean², David M. Hollinshead³ and Claire Landqvist⁴

¹AstraZeneca, Alliance and Project Management, Drug Safety & Metabolism, Melbourn Science Park, Hertfordshire, SG8 6HB, UK

²Charles River Laboratories, Client Services, Safety Assessment, Tranent, Edinburgh, EH33 2NE, UK

³Elixir Software Ltd, Technical Director, Alderley Park BioHub, Macclesfield, Cheshire, SK10 4TG, UK

⁴AstraZeneca, Innovative Medicines and Early Development, IMED RIA, Pepparedsleden 1, 431 83 Mölndal, Sweden

*Corresponding author: Martin, F.D.C. (Frederic.martin1@astrazeneca.com).

Highlights:

- AstraZeneca entered into a strategic relationship with Charles River Laboratories
- The scope was to outsource preclinical safety packages
- New workflows were implemented through the use of a collaborative tool
- The gain in efficiency has positively impacted the AZ portfolio

Teaser: An insight into the AstraZeneca–Charles-River-Laboratories preclinical outsourcing model facilitated by the use of a collaborative tool to gain efficiency and positively impact the AstraZeneca portfolio.

In 2012, AstraZeneca entered into a strategic relationship with Charles Rivers Laboratories whereby preclinical safety packages comprising safety pharmacology, toxicology, formulation analysis, *in vivo* ADME, bioanalysis and pharmacokinetics studies are outsourced. New processes were put in place to ensure seamless workflows with the aim of accelerating the delivery of new medicines to patients. Here, we describe in more detail the AstraZeneca preclinical safety outsourcing model and the way in which a collaborative tool has helped to translate the processes in AstraZeneca and Charles River Laboratories into simpler integrated workflows that are efficient and visible across the two companies.

Keywords: Outsourcing; strategic relationship; collaborative tool; preclinical safety studies.

Introduction

Over the past two decades, the pharmaceutical industry has been faced with new challenging situations impacting productivity and performance [1]. Indeed, the ever-increasing cost of R&D,

Download English Version:

<https://daneshyari.com/en/article/8410093>

Download Persian Version:

<https://daneshyari.com/article/8410093>

[Daneshyari.com](https://daneshyari.com)